Concepedia

H. I. Robins

HI

Statistics

Publications

12

Citations

687

H-Index

12

Active since

1982

Affiliations

University of Wisconsin–Madison(Current)

University of California, San Francisco

University of Lübeck

Memorial Sloan Kettering Cancer Center

The University of Texas MD Anderson Cancer Center

H. I. Robins is an author at University of Wisconsin–Madison specializing in oncology, medicine, and cancer pharmacology.

Publications per year

1982–2014

12

Publications

12

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)

Fábio M. Iwamoto, Kathleen R. Lamborn, H. I. Robins et al. · Neuro-Oncology · 2010 · 219 citations · Full text

, , +17

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

Patrick Y. Wen, Shannon Chang, Kathleen R. Lamborn et al. · Neuro-Oncology · 2014 · 167 citations · Full text

, , +16

A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas

Jeffrey J. Raizer, L. E. Abrey, Andrew B. Lassman et al. · Neuro-Oncology · 2009 · 55 citations · Full text

, , +17

Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05–02)

M. Prados, Mark R. Gilbert, John G. Kuhn et al. · Journal of Clinical Oncology · 2009 · 40 citations

, , +17

A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plustemozolomide: A North American Brain Tumor Consortium study

S. Clifford Schold, John G. Kuhn, Susan M. Chang et al. · Neuro-Oncology · 2000 · 35 citations · Full text

, , +12

1–5 of 12